The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | A novel CD123-targeting antibody-drug conjugate for R/R AML
IMGN632 is a novel antibody-drug conjugate that targets CD123. Here, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the use of this agent in relapsed/refractory acute myeloid leukemia (AML) from the first-in-human study (NCT03386513). This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
